This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
ELISA/assay
product name :
VEGFR3/Flt-4 ELISA
catalog :
DY349B
quantity :
1 Kit (for 5 Plates)
price :
299 USD
citations: 10
Reference
Kumar N, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, et al. Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J Infect. 2017;74:10-21 pubmed publisher
Kumar N, Banurekha V, Nair D, Babu S. Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE. 2016;11:e0146318 pubmed publisher
Tabata T, Petitt M, Fang Hoover J, Rivera J, Nozawa N, Shiboski S, et al. Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation model. Am J Pathol. 2012;181:1540-59 pubmed publisher
Llovet J, Peña C, Lathia C, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290-300 pubmed publisher
Harmon C, DePrimo S, Raymond E, Cheng A, Boucher E, Douillard J, et al. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med. 2011;9:120 pubmed publisher
Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, et al. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther. 2009;17:278-84 pubmed publisher
Rini B, Michaelson M, Rosenberg J, Bukowski R, Sosman J, Stadler W, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3743-8 pubmed publisher
Burstein H, Elias A, Rugo H, Cobleigh M, Wolff A, Eisenberg P, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810-6 pubmed publisher
Lee J, Cho E, Namkung J, Kim E, Kim S, Shin E, et al. Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in Koreans. J Invest Dermatol. 2008;128:1599-603 pubmed
Saltz L, Rosen L, Marshall J, Belt R, Hurwitz H, Eckhardt S, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25:4793-9 pubmed
product information
brand :
R&D Systems
SKU :
DY349B-05
product name :
VEGFR3/Flt-4 ELISA
unit sizes :
1 Kit (for 5 Plates)
description :
The Human sVEGFR3/Flt-4 DuoSet ELISA from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human VEGFR3/Flt-4.
target :
VEGFR3/Flt-4
category :
ELISAs
species :
Human
kit type :
Solid Phase Sandwich ELISA
elisaRange :
93.80 - 6000 pg/mL
catalog number base :
DY349B-05
applications :
ELISA
USD :
299 USD
applications abr :
ELISA
alt names :
EC 2.7.10, EC 2.7.10.1, Flt-4, FLT4, fms-related tyrosine kinase 4, LMPH1A, PCLFLT41, soluble VEGFR3 variant 1, soluble VEGFR3 variant 2, soluble VEGFR3 variant 3, Tyrosine-protein kinase receptor FLT4, vascular endothelial growth factor receptor 3, VEGF R3, VEGFR-3, VEGFR3Fms-like tyrosine kinase 4
storage :
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.